ATARAXIS — switch on the algorithm of precision in the fight against breast cancer
Warsaw Genomics is the official distributor of Ataraxis tests in Poland. We handle test ordering, transport, material scanning and result delivery.
The first fully AI-based diagnostic system
ATARAXIS is the first clinically validated diagnostic system based entirely on artificial intelligence (AI), for patients with invasive breast cancer at stages I–III.
Ataraxis Breast integrates analysis of histopathology slide images with clinical data, giving the physician objective information that helps choose the right systemic treatment.
Key test parameters
Fast analysis and result
The analysis is performed digitally and the result is available within a few business days — so a treatment decision can be made quickly, without waiting weeks for genomic tests.
High precision
In a study of over 10,000 patients, the AI system achieved ~50% higher accuracy in predicting breast cancer recurrence compared with genomic tests.
Material preservation
The analysis is based on a single, already existing slide from a biopsy or surgery — no additional sampling required.
Comprehensiveness
Helps personalise the choice of therapy by assessing recurrence risk, the benefit of adjuvant chemotherapy (in HR+/HER2− patients) and response to neoadjuvant treatment.
Diagnostic parameters per the manufacturer of the Ataraxis Breast system. ATARAXIS supports — and does not replace — the physician's clinical decision.
Ataraxis™ Breast is a tool that supports the oncologist in deciding to de-escalate treatment (avoiding unnecessary chemotherapy) or to intensify it in a targeted way — giving patients therapeutic safety based on hard medical data.
Order the test HERE.
When ordering the test, use the code: ATARAXIS and join the free pilot programme.
Which Ataraxis test should I choose?
The right test depends on the moment of treatment and the molecular subtype of the tumour.
Ataraxis Breast RISK assesses the risk of recurrence in patients with stage I–III invasive breast cancer, regardless of molecular subtype. It answers the question of how high the risk of disease recurrence is within 5 years.
Ataraxis Breast CTX assesses the individual benefit of adding adjuvant chemotherapy to hormone therapy. It is intended exclusively for tumours with hormone receptor expression and without HER2 overexpression (HR+ HER2-), and therefore does not apply to HER2-positive or triple-negative cancers. It answers the question of whether chemotherapy is worth adding to hormone therapy.
Ataraxis Breast NEO assesses the probability of achieving a pathological complete response (pCR) after preoperative treatment, regardless of molecular subtype, lymph node involvement and menopausal status. It is performed on a core-needle biopsy specimen taken at diagnosis, i.e. before surgery. It answers the question of whether treatment preceding surgery has a chance of completely eradicating the tumour.
If your tumour belongs to the HR+ HER2- subtype, the Breast CTX test should be ordered. The same risk of recurrence does not mean the same benefit from chemotherapy; about one quarter of patients classified as high risk derive little benefit from chemotherapy.
Which test is appropriate in a given situation is decided by the treating physician based on disease stage, tumour receptor status and the planned treatment. The test result does not replace medical advice.
Want to order the ATARAXIS test?
Contact us — we will guide you through placing the order and instruct you how to send the sample for analysis.